Metrics as of 10/13/2026, 06:34 PM (Berlin time), refresh in progress.
Lifeward Ltd.
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk,…
1D
-1.0%
1W
-7.6%
1M
-13.2%
6M
-11.6%
YTD
-13.3%
1Y
-29.6%
2Y
-81.2%
5Y
-94.7%
10Y
-99.9%
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~11% weaker price swings than usual
PRICE TARGET LOW
US$10.00
CONSENSUS
US$10.00
MEDIAN
US$10.00
PRICE TARGET HIGH
US$10.00
0
STRONG BUY
4
BUY
0
HOLD
1
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 19/03/2026
P/E
-0.36
P/B
1.37
EV/EBITDA
-0.46
RETURN ON EQUITY
-94.3%
NET MARGIN
-173.9%
DEBT/EQUITY
0.91
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
96.7%
FLOAT SHARES
1,558,385
AVG. DAILY VOLUME (30D)
5,664
Zamir Haggai
Greenwald Yonason
Gabay Avraham
Rose Keith Dale
Lifeward Ltd. is a company in the Healthcare sector, Medical - Devices industry, headquartered in Israel.
The CEO is Joshua Hexter, the company employs around 81 people.
The IPO was on 12/09/2014; the stock trades on NASDAQ under the ticker LFWD.
5 analysts rate the stock, the consensus is Buy (as of 19/03/2026).
The average price target is US$10.00, ranging from US$10.00 to US$10.00, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -11% stronger than usual.
No, Lifeward currently does not pay a dividend.
Comparable stocks include Abbott Laboratories, Medtronic, Stryker, Boston Scientific, Edwards Lifesciences, Siemens Healthineers, DexCom and GE HealthCare Technologies.
Clicking "Analyze stock" lets five strategies assess Lifeward against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.